BioFinlandin jäsen

Glykos is a late preclinical stage biopharmaceutical company working on best-in-class ADCs with outstanding therapeutic index. Glykos has fully developed auristatin, anthracyclin and exatecan linker-payloads for ADC generation, as well as hydrophilic linker for application with novel payloads.